Leukemia
21 videos · last 6 months shuffled daily, then older videos newest first
▶
35:12 Thrombosomes for Severe Bleeding in Leukemia and MDS
Dr. Maro Ohanian of MD Anderson Cancer Center discusses the development of thrombosomes, a freeze-dried platelet-derived product, and a phase 2 randomised trial comparing them with standard platelets in patients with MDS and acute leukemia, for OncoDaily.
▶
8:32 MONVISO: Etentamig Safety in Relapsed Multiple Myeloma
Saurabh Chhabra, MBBS, MS, of Mayo Clinic Arizona discusses safety results from the phase 1b MONVISO study of etentamig, a BCMA x CD3 bispecific, in relapsed or refractory multiple myeloma, for Blood Cancers Today.
▶
26:45 Expanding Blood Cancer Trial Access in the Community
Dr. Gwen Nichols, chief medical officer at Blood Cancer United, discusses overcoming logistical and financial barriers to expanding clinical trial access in community oncology, academic partnerships and hybrid care models, in a SOHO Insider session.
▶
11:35 SOHO 2026 Highlights in Lymphoma, MDS and CLL
Jasmine M. Zain, MD, of Memorial Sloan Kettering, David Sallman, MD, of Moffitt Cancer Center, and Julie M. Vose, MD, of the University of Nebraska Medical Center discuss SOHO 2026 presentations, including phase 2a ofirnoflast results in lower-risk MDS.
▶
4:54 CELESTIAL-TNCLL-2: Sonrotoclax Plus Zanubrutinib in CLL
Mazyar Shadman, MD, MPH, of Fred Hutchinson Cancer Center tells Blood Cancers Today at ASCO 2026 about the phase 3 CELESTIAL-TNCLL-2 trial of sonrotoclax plus zanubrutinib versus venetoclax plus acalabrutinib in untreated CLL, which was recruiting at the time.
▶
6:55 LINKER-SMM1 Assesses Linvoseltamab for High-Risk Smoldering Multiple Myeloma
Paula Rodríguez-Otero, MD, PhD, of the University of Navarra, lead author of the phase 2 LINKER-SMM1 trial, discusses safety and efficacy results for linvoseltamab in high-risk smoldering multiple myeloma, including a May 2026 update, for Blood Cancers Today.
▶
9:32 IRAKLIA: Isatuximab Results by Prior Anti-CD38 Therapy
Sikander Ailawadhi, MD, of the Mayo Clinic Comprehensive Cancer Center discusses a post hoc analysis of the phase 3 IRAKLIA trial of isatuximab with pomalidomide and dexamethasone by prior anti-CD38 therapy, presented at ASCO 2026, for Blood Cancers Today.
▶
19:43 Steven Knapper on a Decade of AML Clinical Trials
Professor Steven Knapper, Chief Investigator of the Cancer Research UK-funded AML18 trial across about 90 centres in the UK and Denmark, reflects on over a decade of AML trials with Cardiff University's Centre for Trials Research.
▶
4:52 A Young Hematologic Oncologist's Research Career
Luis Malpica Castillo, MD, of the Department of Lymphoma-Myeloma at The University of Texas MD Anderson Cancer Center, describes how his clinical research interests began in infectious disease and HTLV-1 and led him to lymphoma, for Blood Cancers Today.
▶
26:01 How Do Clinical Trials Work?
Roswell Park's Smarter Than Cancer follows an acute myeloid leukemia drug from early research through clinical trials to FDA approval with Dr. Eunice Wang, covering who can take part and how researchers judge safety.
▶
9:06 Mayo Clinic Consensus Guidelines for Chronic lySMART 2026
Paul Hampel and Lindsey Roeker of Mayo Clinic review their Mayo Clinic Proceedings article on the Mayo CLL Disease Team's guidelines for frontline and relapsed chronic lymphocytic leukemia.
▶
3:11 How One AML Patient Helped Discover a Life-Saving Cancer Treatment
Paul enrolled in a tissue banking clinical trial after an AML diagnosis more than 20 years ago; his samples were among the first cancer genomes sequenced, leading to the discovery of the IDH1 mutation in AML.
▶
1:36 BeOne Medicines at ASCO 26 on CLL
BeOne Medicines at ASCO 2026 on 78-month follow-up from a Phase 3 study in chronic lymphocytic leukemia, and why durable outcomes matter as much as initial response.
▶
5:12 Ziftomenib FDA Approval for AML
Eunice Wang, MD, Chief of Leukemia at Roswell Park Comprehensive Cancer Center, discusses the FDA approval of ziftomenib for AML and trials testing it with chemotherapy in newly diagnosed and relapsed or refractory disease.
▶
2:16 Alyssa's Story: A Base-Edited CAR-T Cell Therapy Trial
Great Ormond Street Hospital introduces Alyssa, 13, who received base-edited cell therapy for T-cell acute lymphoblastic leukaemia in a GOSH and University College London clinical trial after other treatments failed, and the research team behind the trial.
▶
1:42:41 CELLECTIS R&D Day 2025 - Replay
Cellectis presents the full Phase 1 data set for lasme-cel in B-ALL and the Phase 2 trial design, at its 2025 R&D Day.
▶
1:38 Key Highlights from the Phase 1 Dose Escalation Study of PRGN-3006 UltraCAR-T Presented At
Dr. David A. Sallman of Moffitt Cancer Center discusses highlights from the Phase 1/1b safety study of PRGN-3006 UltraCAR-T in relapsed or refractory CD33-positive acute myeloid leukemia and higher-risk myelodysplastic syndromes.
▶
13:33 Moleculin CEO on Annamycin Trial Data in AML and Sarcoma
Moleculin CEO Walter Klemp discusses 2023 year-end preliminary data from Annamycin clinical trials in acute myeloid leukemia and soft tissue sarcoma lung metastases.
▶
8:20 Real World Evidence Used to Compare Ibrutinib to Acalabrutinib in Chronic Lymphocytic Leukemia
Physician uses "real world evidence" or "real world data" to evaluate ibrutinib versus acalabrutinib in Chronic lymphocytic leukemia ( CLL ) patients and discusses the drawbacks of using RWE versus prospective studies.
▶
2:49 Faecal Microbiota Transplant Trial in Graft-versus-Host Disease
QIMR Berghofer describes a clinical trial led by Dr Andrea Henden at the Royal Brisbane and Women's Hospital testing faecal microbiota transplant in blood cancer survivors with severe graft-versus-host disease after bone marrow transplant.
▶
6:09 Annamycin: A Next-Generation Anthracycline
Moleculin Biotech on Annamycin, a next-generation anthracycline in trials for relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases.